Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
milademetan (2 trials)
trabectedin (yondelis) (1 trial)
sotorasib (LUMAKRAS) (1 trial)
tarloxotinib (2 trials)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Trials (4 total)
Trial APIs (4 total)